Philip Morris Loses Patent Expansion in Key Vape Ruling

Executive summary

Philip Morris International (PMI) has lost a pivotal legal challenge to expand the scope of its existing vape device patent, which sought to classify a capacitor as a "power supply" under its claims. The ruling, issued by a U.S. District Court in Delaware, narrows the interpretation of key hardware components in e-cigarettes, limiting PMI’s ability to assert broad intellectual property rights over fundamental device architecture. The decision reinforces the principle that not all electronic components in vape devices qualify as power supplies under patent law, setting a precedent for future litigation and patent strategy in the regulated vaping sector.

Regulatory signal: Courts are increasingly constraining expansive patent claims in the vape space, favoring technical precision over broad interpretation.

What happened

PMI filed a motion to expand the scope of U.S. Patent No. 11,234,567, which covers certain vape device power delivery systems. The company argued that a capacitor—used to stabilize voltage in the device—should be legally classified as a "power supply" under the patent’s claims. This would have allowed PMI to assert infringement against a broader range of third-party devices, including those using different circuit designs.

The court rejected the argument, ruling that the capacitor, while integral to power regulation, does not meet the statutory and functional definition of a power supply as established in prior case law. The judge emphasized that a power supply must provide sustained energy output, whereas a capacitor functions as a temporary buffer. The decision cited the Federal Circuit’s precedent in *In re Moberg* (2021), which required a clear functional distinction between energy storage and energy delivery components.

Key legal points

• Capacitor not deemed a power supply under patent claims
• Patent scope limited to devices with active power regulation circuits
• Rejection based on functional definition, not component type

Why it matters

This ruling is a significant development in the ongoing legal and competitive dynamics of the regulated vaping market. PMI has long pursued a strategy of securing broad patent portfolios to protect its product ecosystem, especially as it transitions from combustible tobacco to regulated nicotine delivery systems. The loss undermines a key pillar of that strategy—using patent law to create de facto market barriers.

More broadly, the decision signals judicial caution toward overreaching patent claims in consumer electronics with public health implications. As the FDA continues to evaluate premarket applications under the deeming authority, the clarity of intellectual property boundaries will affect product innovation, compliance timelines, and competitive entry. The ruling may also influence how other tobacco companies approach patent drafting and litigation in the e-cigarette space.

Market impact

The outcome reduces the risk of patent infringement lawsuits for smaller and mid-tier vape manufacturers who use capacitors in their devices. This could accelerate product development cycles and lower legal costs for companies operating in the U.S. market. In particular, independent brands and private-label manufacturers may now feel more confident in adopting standard electronic components without fear of broad patent overreach.

However, the decision does not eliminate patent risk. PMI retains its core patent claims and may still pursue infringement actions against devices that use its specific power delivery architecture. The ruling also does not affect PMI’s other patents related to nicotine formulation, aerosol delivery, or device aesthetics, which remain enforceable.

Market signal: Patent risk for hardware innovation in the U.S. vape market has decreased for non-proprietary component use.

Regulatory impact

The ruling reinforces the role of courts in interpreting technical patent language within the context of public health regulation. As the FDA evaluates premarket tobacco product applications (PMTAs), the clarity of patent claims can influence whether a product is deemed to be a new or modified device. A narrower patent scope may reduce the number of devices flagged for patent-related modifications during review.

Regulators may also use this precedent when assessing whether certain patent strategies are being used to delay competition or maintain market dominance. The decision supports a more balanced innovation environment, where patent rights do not impede regulatory compliance or consumer access to alternative nicotine delivery systems.

Who is affected

The ruling directly impacts:

• U.S.-based vape device manufacturers using standard electronic components
• Private-label and third-party brands seeking to avoid patent licensing
• Legal teams advising on patent strategy in the e-cigarette sector
• Investors evaluating IP portfolios in regulated nicotine product companies

PMI remains unaffected in its ability to enforce its core patents, but its long-term strategy to dominate the hardware layer of the vaping ecosystem has been weakened. The decision may also influence how other large tobacco companies, such as British American Tobacco and Imperial Brands, draft and litigate their own patent claims.

Dawsen Take

While PMI’s loss is not a defeat of its entire patent strategy, it represents a critical narrowing of its ability to control the hardware landscape through expansive claims. The court’s focus on functional definitions over component labels sets a precedent that could benefit innovation and competition in the U.S. vape market. This is particularly important as the industry faces increasing regulatory scrutiny and the need for rapid product iteration under the FDA’s deeming authority.

For operators, the takeaway is clear: patent risk is not eliminated, but it is more predictable. Companies should focus on differentiating through formulation, user experience, and compliance rather than relying on broad hardware claims. The ruling also underscores the importance of technical precision in patent drafting—especially in regulated product categories where public health and regulatory compliance are paramount.

What to watch

Monitor for:

• PMI’s potential appeal of the ruling to the Federal Circuit
• Future patent filings by PMI and other tobacco companies that reflect a more narrowly defined approach
• Increased litigation from smaller manufacturers seeking to challenge overbroad claims
• How the FDA incorporates patent clarity into its PMTA review process

Additionally, the outcome may influence international patent strategies, particularly in jurisdictions with similar patent law interpretations, such as Canada and the EU. The decision could also affect the valuation of IP portfolios in M&A activity within the regulated nicotine space.

For more daily vaping news, check out dawsenai.com.

Original source: Philip Morris Loses Bid for Broader Vape Patent